Cohort Saga Selects SMART-TRIAL for Study on How Trauma Impacts Women’s Health

Jón Ingi Bergsteinsson, MEDEI’s vice-president of global business development

SMART-TRIAL software will be used in a large, decade-long nationwide research project where 110,000 Icelandic women are invited to participate

One of our most important decisions was to select a scaleable data management solution for the project. Due to the sensitive topic and large target size, we had high demands on security and usability”

— Unnur A. Valdimarsdóttir

AALBORG, DENMARK, June 19, 2018 /EINPresswire.com/ — The SAGA cohort is one of the largest research projects ever undertaken to specifically address the potential impact of trauma or severe adversities on women’s health and the potential genetic contribution to varying health trajectories after such trauma exposure. The project Cohort Saga (http://afallasaga.is/en/) is undertaken by investigators at the University of Iceland in collaboration with deCODE Genetics.

During the course of their lives, most people are exposed to trauma or severe adversities. Women are frequently subjected to violence and often it happens early in their lives. The World Health Organization estimates that one in every three women are subjected to sexual or physical violence at some point. Accumulating evidence suggests that such trauma may affect both psychological and physical health. However, large research programs are still needed to significantly advance the understanding of the complex association between trauma exposure and long-term morbidities.

In all, around 110,000 Icelandic women will be invited to participate in the SAGA cohort by answering an online questionnaire on trauma history and health and by signing an informed consent for tracking of medical diagnoses and biomarkers in existing healthcare databases and biobanks during the coming decades. The project takes advantage of MEDEI’s excellent software for data management and collection.

"One of our most important decisions was to select a scaleable data management solution for the project. Due to the sensitive topic and the large target size, we had high demands on both security and usability. We believe we made the right decision by selecting SMART-TRIAL, because it meets our requirements for both compliance and a user-friendly interface," says Unnur A. Valdimarsdóttir, Cohort Saga’s Principle Investigator and Project Guarantor.

“MEDEI is proud to be associated with such a large and prestigious humanitarian research project,” adds Jón Ingi Bergsteinsson, MEDEI’s vice-president of global business development. “Our innovative and scalable SMART-TRIAL software platform is designed for such large projects and will help Cohort Saga to simplify and better manage the on-going collection of data from this nationwide research project.”

About MEDEI

MEDEI ApS is a Danish medical software innovator that delivers industry-leading software to medical device manufacturers and clinical research. The firm’s flagship product SMART-TRIAL is a unique data management platform that helps reduce chaos and improves the collection and management of clinical data. Visit https://www.smart-trial.co

Ends

Hugh Paterson
Whoosh PR
+447768175452
email us here


Source: EIN Presswire